CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases. [Read more…]
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
– FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology
– The agreement enables drug developers to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements
Organicell Provides Update on Its COVID-19 Clinical Trial Using Zofin™
-
Anticipates Phase I/II trial completion by end of year
-
Anticipates Phase IIb trial to begin in Q1 2021
-
Seeks to retain a global contract research organization (“CRO”)
Miami, FL (November 12, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for treatment of COVID-19 using Organicell’s proprietary therapeutic, Zofin™, which is currently underway as well as an update on its expanded access protocol for outpatients with COVID-19. [Read more…]
Trailhead Biosystems Raises $6.6 Million in Series A Financing
Therapeutic cell pioneer Trailhead Biosystems raises Series A funding for development of specialized human cells
Financing will expand the company’s High Dimensional Design of Experiments platform (HD-DoE), support the generation of multiple specialized human cells with therapeutic properties and their pilot scale manufacturing
CLEVELAND, Ohio, November 10th, 2020. Trailhead Biosystems Inc. (www.trailbio.com) – a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology – announced its $6.6 million Series A financing. The company has developed a proprietary platform to perform systems-level interrogation of complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies. [Read more…]
StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvoTM Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes
Matrix Plus promotes functional and structural maturation of hiPSC-CMs in seven days compared to partial maturation obtained within 30 to 100 days with current approaches
SAN ANTONIO and ANN ARBOR, Mich., Nov. 9, 2020 — StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) in culture and enables high throughput cardiotoxicity screening using mature human cardiomyocytes.
[Read more…]
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 117
- Next Page »